189 related articles for article (PubMed ID: 26831408)
21. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
22. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH
Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802
[TBL] [Abstract][Full Text] [Related]
23. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma.
Liu PH; Hsia CY; Lee YH; Hsu CY; Huang YH; Su CW; Lee RC; Lin HC; Huo TI
J Surg Oncol; 2015 Mar; 111(4):404-9. PubMed ID: 25643842
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
25. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.
Riaz A; Ryu RK; Kulik LM; Mulcahy MF; Lewandowski RJ; Minocha J; Ibrahim SM; Sato KT; Baker T; Miller FH; Newman S; Omary R; Abecassis M; Benson AB; Salem R
J Clin Oncol; 2009 Dec; 27(34):5734-42. PubMed ID: 19805671
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
[TBL] [Abstract][Full Text] [Related]
27. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
[TBL] [Abstract][Full Text] [Related]
28. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
[TBL] [Abstract][Full Text] [Related]
29. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy.
Kao WY; Chiou YY; Hung HH; Su CW; Chou YH; Wu JC; Huo TI; Huang YH; Wu WC; Lin HC; Lee SD
Clin Radiol; 2012 May; 67(5):429-36. PubMed ID: 22153231
[TBL] [Abstract][Full Text] [Related]
30. Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal.
Blank S; Wang Q; Fiel MI; Luan W; Kim KW; Kadri H; Mandeli J; Hiotis SP
Ann Surg Oncol; 2014 Mar; 21(3):986-94. PubMed ID: 24232510
[TBL] [Abstract][Full Text] [Related]
31. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.
Kaplan DE; Mehta R; D'Addeo K; Gade TP; Taddei TH
J Vasc Interv Radiol; 2018 Apr; 29(4):540-549.e4. PubMed ID: 29477619
[TBL] [Abstract][Full Text] [Related]
32. Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
Schmidt L; op den Winkel M; Fischer K; Straub G; Rauch B; Paprottka PM; Göke B; Kolligs FT
Digestion; 2014; 90(4):219-28. PubMed ID: 25502689
[TBL] [Abstract][Full Text] [Related]
33. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
Memon K; Kulik L; Lewandowski RJ; Wang E; Ryu RK; Riaz A; Nikolaidis P; Miller FH; Yaghmai V; Baker T; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R
J Hepatol; 2012 May; 56(5):1112-1120. PubMed ID: 22245905
[TBL] [Abstract][Full Text] [Related]
34. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A
J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
37. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
[TBL] [Abstract][Full Text] [Related]
38. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
39. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
